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THE EFFECTS OF XANTHIGENTM SUPPLEMENTATION ON BODY
COMPOSITION, SERUM MARKERS OF THE METABOLIC SYNDROME, AND
HEPAPTIC ENZYME LEVELS IN AN OBESE POPULATION
XanthigenTM [100 mg brown seaweed extract (0.8 % fucoxanthin) and 100 mg
pomegranate seed oil (70 % punicic acid)] has been shown to significantly reduce body
fat, liver fat, and improve serum markers of liver function in obese females. Twenty-nine
participants were matched for age, gender, and body fat percentage and randomized into
either a XanthigenTM group or a placebo group. For 16-weeks, participants were asked to
consume a reduced calorie diet while supplementing their diet with their respective pills
three times per day. Data were analyzed using multivariate ANOVA with repeated
measures and presented as mean ± standard deviation. While most participants saw
weight loss, body fat percentage did not significantly change, indicating that weight loss
was from both fat mass and lean mass. Significant changes were seen in serum levels of
alkaline phosphatase (ALP), alanine transaminase (ALT), total protein, and albumin. The
changes in both the placebo and Xanthigen groups were similar, however. No significant
changes were seen in other serum markers, but there was a trend for a reduction in
triglycerides with a statistical trend for a greater decrease in the Xanthigen group. While
both placebo and Xanthigen groups experienced weight loss and reduced liver enzyme
levels, the Xanthigen supplementation did not produce significant results.
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THE EFFECTS OF XANTHIGENTM SUPPLEMENTATION ON BODY
COMPOSITION, SERUM MARKERS OF THE METABOLIC SYNDROME, AND
HEPAPTIC ENZYME LEVELS IN AN OBESE POPULATION

Chapter 1: Problem Statement
Over the past two decades in the United States, the incidence of overweight and
obesity has been a rising trend (Center for Disease Control and Prevention [CDC],
2011a). Although the dramatic increase in these numbers has begun to diminish, more
than half of the states in the U.S. had a twenty-five percent or greater obesity rate as of
2009 (CDC, 2011a). Furthermore, nine states, mostly in the south, have obesity rates of
greater than thirty percent (CDC, 2011a). In addition to the large number of Americans
that are obese, thirty-four percent of all Americans are overweight (CDC, 2011a). The
problem created by this great prevalence of overweight and obesity is that these
individuals are at a greater risk for the development of other diseases. According to the
National Heart, Lung, and Blood Institutes, overweight and obesity lead to an increase in
the morbidity rate of diseases such as hypertension, Type II diabetes, coronary heart
disease, stroke, various forms of cancer, and many other dangerous diseases (National
Health Institutes, 1998; Pi-Sunyer, 2002). Along with the increasing morbidity rates,
individuals with a body-mass index (BMI) greater than thirty have a 50 to 100 times
greater risk of all-cause mortality, especially due to cardiovascular disease (National
Health Institutes, 1998; Pi-Sunyer, 2002).
Because overweight and obesity are such common problems, many studies have
attempted to determine appropriate ways to combat them. A proper diet and physical
activity are two of the main factors in the cure for obesity, but often times they are not
enough. Since healthy diet and regular physical activity may not be practical options for
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all Americans, many nutritional supplements have entered the market that promise to
promote weight loss. In recent years, a nutritional supplement called Xanthigen has been
produced and testing has begun on its anti-obesity effects. Abidov and colleagues
(Abidov, Ramazanov, Seifulla, & Grachev, 2010) conducted studies on obese women
using Xanthigen supplementation to determine the physiological changes elicited by the
supplement. This study reported that Xanthigen was well tolerated, reduced body weight,
body fat, and waist circumference. Additionally, all groups had a reduction in serum
triglycerides and in liver enzymes. Xanthigen has proven to be safe and effective thus far,
quite possibly providing Americans with a “quick fix” to their weight problems.
Because Xanthigen is new to the market, very little testing has been completed on
this supplement. Abidov and his fellow researchers (2010) used only obese women in
their study, and thus present results are very exclusive to a certain population. To gain
more knowledge about the Xanthigen supplement, a broader study must be done
including men and women of broader age categories. In the study at hand, the effects of
Xanthigen supplementation on obese men and women was assessed by examining body
composition, lipid levels [triglycerides, high-density lipoproteins (HDL), low-density
lipoproteins (LDL), and total cholesterol levels], liver enzymes [alanine aminotransferase
(ALT), aspartate aminotransferase (AST), and γ-glutamyltransferase (GGT)], and glucose
and insulin concentrations in the blood. In this study, obesity was defined as individuals
with a BMI of greater than 30 kg/m2. This particular study was a 16-week double blind
experiment. It was hypothesized that with Xanthigen supplementation, body composition
would improve (body fat percentage decrease), lipid levels improve (triglyceride and
LDL decrease, but HDL increase), liver enzymes levels improve (decrease), and glucose
2

concentrations would improve (decrease). Many of the results of this study are contrary
to Abidov’s study (2010), thus leading to new potential studies to further elucidate the
mechanism and effectiveness of Xanthigen supplementation.
Chapter 2: Literature Review
Obesity
Over the past two decades, obesity has become a major health concern worldwide.
According to the CDC, adult obesity has been defined as a body-mass index (BMI) of
greater than 30 kg/m2 (CDC, 2011b). Since the 1980s, obesity has reached epidemic
proportions worldwide. In the United States alone, almost one hundred million people
suffer from the effects of overweight and obesity (National Health Institutes, 1998; PiSunyer, 2002). As of 2005, nearly one-third of all US adults were classified as obese
(Baskin, Ard, Franklin, and Allison, 2005). The CDC reports that in 2009, 33 states
reported 25% or greater obesity rates (CDC, 2011a). Additionally, nine states had obesity
rates of 30% or greater (CDC, 2011a). Of these nine states, Mississippi held the highest
obesity rate, with 34.4 percent of all Mississippians being obese (CDC, 2011a). It is
predicted that by the year 2020, greater than 40% of men and greater than 43% of women
will be considered obese (Ruhm, 2007). This great prevalence of obesity poses concerns
for all.
Obesity is closely linked with many other diseases and higher mortality rates than
what is seen in a normal, healthy population. Excessive body weight alone is linked with
hypertension, type II diabetes mellitus, coronary heart disease, gallbladder disease,
osteoarthritis, sleep apnea, respiratory problems, and some types of cancer (National
Health Institutes, 1998; Pi-Sunyer, 2002). As BMI increases, blood pressure increases
3

proportionally (Must et al., 1999). According to the National Health Institutes (1998),
between thirty and forty percent of all obese people have hypertension. These increases in
blood pressure are also correlated with increases for the likelihood of stroke and coronary
heart disease (National Health Institutes, 1998; Pi-Sunyer, 2002). Along with
hypertension, obesity is also related to dyslipidemia. As is the case with blood pressure,
serum lipid levels rise with weight gains. Obese persons see rises in total cholesterol,
triglycerides, and LDL (National Health Institutes, 1998; Pi-Sunyer, 2002). Increases in
obesity are often also linked to an increased death rate (Flegal, Graubard, Williamson,
and Gail, 2005).
Another issue raised by the prevalence of obesity is the cost to care for those who
are obese. Previously it was estimated that on an annual basis, obese individuals’
healthcare costs about $395 more than normal adults (Finklestein, Fiebelkom, and Wang,
2003). This was an increase of about 36%. More recent numbers indicate that obesity
costs approximately $732, or 37.4% more than adults of a healthy body weight. About
5.3% of all medical spending is put towards obesity-related expenses. With these
statistics, the monetary costs of overweight and obesity are quickly becoming rivals to the
monetary costs of smoking (Finklestein et al, 2003).
Lipids and Obesity
Like many other issues, obesity is strongly linked with dyslipidemia, including
hypertriglyceridemia and hyperlipidemia. According to the American Heart Association
(AHA, 2011), triglycerides are “the chemical form in which most fats exist in food as
well as in the body.” While normal triglyceride levels are considered less than 150
mg/dl, someone with elevated triglycerides, or hypertriglyceridemia, will have over 200
4

mg/dl (AHA, 2011). Although there are five major families of lipoproteins, dyslipidemia
primarily focuses on HDL, LDL, and total cholesterol. HDL is considered “good”
cholesterol. To be protected against heart disease, one should have an HDL level of at
least 60 mg/dl (AHA, 2011). A person whose HDL levels fall below 50 mg/dl (for
women) or 40 mg/dl (for men), are considered to be at greater risk for heart disease
(AHA, 2011). LDL is considered “bad” cholesterol. Optimal LDL levels are less than 100
mg/dl, while high LDL levels reach above 130 mg/dl (AHA, 2011). For healthy
individuals, total cholesterol should be less than 200 mg/dl (AHA, 2011). Any person
with total cholesterol of greater than 200 mg/dl more than doubles their risk for heart
disease (AHA, 2011).
It has been shown that among the obese, hypertriglyceridemia is almost two times
more likely to occur than in the non-obese (Kaplan, 1989). “Obesity is probably the
metabolic stressor most frequently associated with hypertriglyceridemia…” (Yuan, AlShali, and Hegele, 2007). The combination of obesity and non-alcoholic fatty liver
disease (NAFLD) also correlates with elevated triglycerides and low HDL levels (Yuan
et al., 2007). Similarly, obesity is related to the metabolic syndrome. Features of the
metabolic syndrome include elevated triglycerides and lowered HDL levels (Hardman,
1999). The connecting factor here is lipoprotein lipase (LPL), which is the enzyme
responsible for breaking down triglycerides (Hardman, 1999). With a dysfunction in
LPL, triglycerides are not appropriately removed, and are rather dissociated (Hardman,
1999). Parts of this dissociation, including free cholesterol, may be transferred to HDLs,
thus changing their make-up (Hardman, 1999). According to Kannel and colleagues
(1979), HDL seems to be the lipoprotein most strongly related to obesity (Kannel,
5

Gordon, and Castelli, 1979). As HDL levels have an inverse relationship with obesity,
total cholesterol levels often have a positive correlation with obesity. As BMI increases,
so does serum cholesterol levels (Brown et al., 2000).
Liver Enzymes and Obesity
Elevated transaminase levels are often of concern when looking at obesity. Liver
enzyme levels can be elevated for multiple reasons. Although alcoholic liver disease is
often a cause of elevated transaminases, NAFLD can also be a major underlying cause of
this problem (Palmer, 2004a; Palmer, 2004b). Alanine aminotransferase (ALT) and
aspartate aminotransferase (AST) are the known markers for hepatocellular injury
(Kundle, Lazenby, Clements, and Abrams, 2005). In obese youth populations, NAFLD is
considered the primary reason for elevated ALT (Burgert et al., 2006). It has been found
that with NAFLD, elevated ALT is the most common liver abnormality (Kerner, et. al.,
2005). Elevated ALT levels often indicate liver damage and may be predictors of type 2
diabetes mellitus (Burgert et al., 2006). Burgert and colleagues hypothesized that elevated
ALT may be a cause of defective glucose and insulin metabolism, and increases in freefatty acids and triglycerides.
NAFLD is defined as “a condition of fat accumulation in the liver in the absence
of excessive alcohol consumption and any other specific causes of hepatic steatosis,”
(Bellentani and Marino, 2008). Although not completely understood, NAFLD is clearly
linked with insulin resistance, and may often accompany obesity, as well as type 2
diabetes (Bellentani and Marino, 2008). According to publications in Arteriosclerosis,
Thrombosis, and Vascular Biology , NAFLD affects an estimated 25% of the American
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population (Kerner et al., 2005). Complications with NAFLD include a link to further,
more damaging, and often fatal liver disease, as well as cardiovascular disease
(Bellentani and Marino, 2008).
Fucoxanthin
Edible seaweeds are very nutritious and are often full of nutritional benefits such
as fiber, nutrients, and some minerals (Yan, Chuda, Suzuki, and Nagata, 1999).
Fucoxanthin is a carotenoid found in Undaria pinnatifida that has been researched for its
anti-obesity effects. In a study done by Maeda and colleagues (2005), edible seaweed
(fucoxanthin) was fed to rats and mice and this study anti-obesity effects of fucoxanthin.
Obese mice given a diet supplemented with 2% fucoxanthin saw a great reduction in the
weight of their white adipose tissue. Through the results of these studies, it was
determined that an increase in heat production from oxidation of fats will produce less
incidence of diabetes (Maeda etal, 2005).
Maeda and colleagues (2008) also found that fucoxanthin can produce effects
that have yet to be found in other dietary seaweed carotenoids, including, anti-obesity and
anti-diabetic effects. Through multiple studies in rodents and cell cultures, Maeda et al.
(2005, 2008) found fucoxanthin to be an upregulator of uncoupling protein-1 (UCP-1)
(Maeda et al, 2005; Maeda et al, 2008). This being said, upregulating UCP-1 is the
alteration that produces the desired anti-obesity results. Furthermore, the presence of
UCP-1allows for uncoupling of cellular respiration, which promotes the usage of fatty
acids, and therefore promotes resistance to obesity (Ricquier, 2005). Fucoxanthin
supplementation also led to an increase in docoshexaenoic acid (DHA) production,
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which, in turn, led to an increase in the fat burning process of beta-oxidation (Maeda et
al, 2008).
Pomegranate Seed Oil
Pomegranate seed oil (PSO) contains a type of conjugated linolenic acid (CLN)
called punicic acid (Yamasaki et al., 2006). In this study from Yamasaki and colleagues,
mice were fed different dosages of PSO to determine its immunological effects. Many
changes in immunoglobin production were observed; and contrary to what might be
expected, PSO supplementation resulted in increased triglycerides, but did not affect the
weight of adipose tissue (Yamasaki, et. al., 2006). The conclusions of this study were that
PSO supplementation modulates lipid metabolism and promotes immunoglobin
production, possibly producing desirable effects (Yamasaki, et. al., 2006).
Similarly, Arao, Yotsumoto, Han, Nagao, and Yanagita (2004b) discovered other
effects of CLN. Rather than investigating immunoglobins and triglycerides, Arao and
colleagues examined the relationship between apolipoprotein B100 (ApoB100) secretion
and human liver derived cells, known as HepG2 cells. The findings of this study indicate
that: CLN has the ability to suppress apoB100 secretion in the liver through the
suppression of triglyceride synthesis in HepG2 cells. In conclusion, Arao’s study stated
the possibility of using 9c,11t,13c-CLN as a hypolipidemic component (Arao, Yotsumoto
et al., 2004b).
In a study similar to the Yamasaki study (2006), rats were used to investigate the
dietary effects of CLNA on lipid metabolism (Arao, Wang et al., 2004a). In one group of
rats, obesity-like effects were induced. When comparing the obese rats to another
8

“control” group, it was determined that triglyceride concentration in the liver was
significantly lowered by a diet including CLN (Arao, Wang et al., 2004a). It was decided
that this was due to the suppression of delta-9 desaturation (Arao, Wang et al., 2004a).
These previously mentioned studies have shown that through many mechanisms,
pomegranate seed oil may produce desirable results.
Xanthigen
Although proper diet and regular exercise are simple solutions for obesity, lack of
compliance often impairs their results. In recent years, researchers have combined the
anti-obesity effects of fucoxanthin and the positive effects of pomegranate seed oil to
create a dietary supplement that can safely and effectively treat obesity. Through this
combination, Xanthigen was born.
Abidov and his colleagues (2010) studied Xanthigen and its effects during a 16week, double-blind study on obese, premenopausal women. To do so, the Abidov
research team recruited obese, premenopausal, non-diabetic women presenting with or
without NAFLD (Abidov et al., 2010). A group of 72 women with NAFLD participated,
while a group of 38 with normal liver fat also participated. The NAFLD group was split
into two groups of 36, one control group and one Xanthigen group. NLF participants
were also split into two equal groups (n=19), with one control group and one Xanthigen
group. Another group of 41 women diagnosed with NAFLD was used specifically to
measure changes in resting energy expenditure (REE). REE groups were further
subdivided into: a placebo group, a Xanthigen-200/0.8 mg group, a Xanthigen-400/1.6
mg group, a Xanthigen-600/2.4 mg group, a Xanthigen-1000/4 mg group, a fucoxanthin1.6 mg group, a fucoxanthin-2.4 mg group, a fucoxanthin-4.0 mg group, a fucoxanthin9

8.0 mg group, a PSO-1500 mg group, and a PSO-2000 mg group. All food was provided
to the participants throughout the duration of the study and their diets were restricted to
1800 calories. Respective supplements were to be taken three times a day 15-30 minutes
before each meal. A visit was required three times per week for measures to be taken.
Total weight and body fat were measured upon beginning the trial. Dual-energy
X-ray absorptiometry was used to analyze body fat content. Liver fat content was
quantified using proton magnetic resonance spectroscopy. Resting energy expenditure
was measured using indirect calorimetry. Blood samples were taken and analyzed for
ALT, AST, GGT, c-reactive protein (CRP), and triglycerides.
In the end, it was determined that Xanthigen and both of its components were
well tolerated by all participants with no adverse effects reported. In this population, a 10
pound or greater reduction in body weight was seen in groups supplemented with
Xanthigen (Abidov et al, 2010). Although the placebo groups also lost weight, the
Xanthigen supplemented group lost significantly more weight than did those participants
who were given the placebo. Along with body weight improvements, body fat and,
incidentally, liver fat percentages were also decreased. When looking at body fat and
liver fat percentages, the placebo group saw no changes from the beginning of the study
to the end. As might be expected due to the decrease in body weight, waist circumference
also decreased in the Xanthigen supplemented group. The placebo group saw little to no
changes in their waist circumference measures. Although serum triglyceride levels were
reduced, they were not reduced significantly versus the control group except in the
NAFLD group, where significant reduction was seen. Liver enzyme levels improved, as
did C-reactive protein levels. These levels were significant compared to the placebo
10

groups. At certain concentrations, REE was significantly increased. Ultimately, Abidov
and his colleagues (2010) determined that Xanthigen-600/2.4 was the best combination
that safely produced many desired results to help combat overweight and obesity.
The study at hand sought to determine the effects of Xanthigen supplementation
on an obese population. Through a 16-week, double-blind study, many changes were
examined. It was expected that body composition, specifically body fat percentage, blood
lipids, including triglycerides, HDL levels, LDL levels, and total cholesterol, certain liver
enzymes, and glucose concentrations would all improve. Although Xanthigen
supplementation was the most important factor in weight loss, participants were also
placed on slightly restricted calorie diets to combat this confounding variable as much as
possible. This being said, exercise still played a small role as another confounding
variable that was monitored.
Chapter 3: Methodology
This study was a modified replication of Abidov and his colleagues’ original
study on Xanthigen supplementation (2010). The methods used in the study at hand
followed closely with the previous study’s methodology. After recruiting 58 participants,
31 obese, non-diabetic participants between the ages of 18 and 50 completed a 16-week
double-blind study assessing the effects of Xanthigen supplementation on body
composition, serum lipoprotein levels, and liver enzymes. Participation was open to
males and females in the Hattiesburg area who met the following criteria: between ages
18 and 50, pre-menopausal, qualify as being obese (BMI of greater than 30 kg/m2), must
not be pregnant, must not have any known metabolic disorders, must not have taken any
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thyroid, hyperlipidemic, hypoglycemic, anti-hypertensive, androgenic medications, or
nutritional supplements known to influence fat metabolism within the past six month,
must not have had a history of excessive alcoholic consumption. Participants were
recruited from USM and the Hattiesburg area via word-of-mouth, email announcements,
and online postings. All data collection was completed by the lead investigator or
research assistants in the USM Laboratory of Applied Physiology.
After recruiting participants, they were separated into two experimental groups: a
placebo group and a Xanthigen supplement group. Participants were grouped according
to gender, age, and body fat percentage before being placed into either the placebo or
Xanthigen groups using a randomized, double-blind procedure. To uphold the integrity of
the double-blind aspect of this study, placebo capsules were packaged identically to the
Xanthigen capsule, but were instead filled with 200 mg extra virgin olive oil. Xanthigen
capsules were comprised of a combination of 100 mg of pomegranate seed oil and 100
mg of brown seaweed extract with 0.8 mg of fucoxanthin.
Participants were first familiarized with the purpose, design, risks, and benefits
associated with the study. After any questions were answered by the lead investigator or
research assistants, an Informed Consent form and medical history questionnaire were
completed by the participants. At the initial testing session (T1) research assistants
assessed baseline body mass, height, blood pressure, waist circumference, total body
water (via bioelectrical impedance analysis), REE, and body composition (via Dual
Energy X-ray Absorptiometry). The first samples of blood were also drawn by the lead
investigator at this time. Blood was drawn the morning after an overnight fast using
standard phlebotomy techniques. Serum samples were left standing at room temperature
12

for 10 minutes before being centrifuged. At the conclusion of T1, participants were
randomly divided into placebo or supplement groups according to gender, age and body
fat percentage.
Upon the conclusion of T1, participants were given dietary counseling concerning
supplementation and the required standardized diet by a dietician. Two weeks of
supplements were handed out at this time with directions instructing the participant to
take their particular pills three times per day at 15-30 minutes prior to mealtime.
Participants were placed on standardized diets throughout the 16-week study. A diet
based on the Dietary Exchange Program was used to allow participants some freedom in
their dietary choices, but still maintain a constant caloric intake. Caloric intake was
determined according to each participant’s resting energy expenditure. Because of this
freedom, participants were required to turn in four-day food logs every two weeks.
Additional dietary counseling was provided if participants were found to be struggling
with compliance or have additional questions concerning their diets. To encourage
participants’ continued participation in the study, participants were only given two
weeks’ worth of supplement upon each visit.
Testing session 2-5 (T2-5) occurred during weeks four through 16. Data
collecting sessions occurred every four weeks throughout the study, although participants
were still required to pick-up their next set of supplements and drop off food journals
every two weeks. During testing sessions, participants reported to the Laboratory of
Applied Physiology to have body mass, blood pressure, waist circumference, total body
water, body composition, and REE assessed by research assistants. Another blood sample
was also taken by the lead investigator upon each of these visits. Serum levels of
13

triglycerides, HDL, LDL, total cholesterol, glucose, AST, and ALT were assessed by
medical technologists at the USM Health Services Clinic.
During each testing session, multiple tests were conducted. Each of these tests had
a very specific procedure. First, the anthropometric measurements such as total body
mass and waist circumference were performed using a standard digital scale (Ohaus
Champ II) and standard anthropometric measurements, respectively (Pollock, Jackson,
1984). These measures were collected and recorded by research assistants. Total body
water was measured using bioelectrical impedance analysis (BIA; Tanita TBF-310GS).
Percent body fat, fat mass, and fat-free mass were determined using dual energy X-ray
absorptiometry (DEXA; GE Lunar Prodigy), and conducted by research assistants.
Resting energy expenditure (REE) was assessed using the Vyasis Vmax Encore
metabolic cart. Through the use of a transparent canopy connected to a gas mixing
chamber, metabolic measurements were taken. To obtain these measurements,
participants remained in a supine position for approximately 25 minutes without falling
asleep. During these 25 minutes, respired gases were analyzed and oxygen uptake and
carbon dioxide production was measured. These measurements were then used to
calculate the participants’ REE and respiratory quotient (RQ). To assure that the
combination of diet, exercise, and supplementation were safe, hemodynamic measures
were taken and recorded during each session. Both blood pressure and heart rate were
taken twice while resting with an automated blood pressure monitor (Omron HEM
907XL) and the average of the two results recorded by the research assistant.
As previously mentioned, participants were required to keep four-day food
journals every two weeks. Dietary records were collected and entered into dietary
14

assessment software by research assistants. Finally, records were analyzed using the Food
Processor dietary assessment software program (ESHA Research, Inc., Salem, OR).
Blood samples taken by the lead investigator during T1-T5 were drawn using
standard sterile venipuncture technique. Samples were taken from the antecubital vein
using standard phlebotomy procedures. Samples were taken only by the primary
researcher or phlebotomists at the USM Health Services Center. Gloves and other safety
equipment were always used when taking and handling blood samples. To obtain
samples, participants were seated in a chair and had their arms cleaned with a sterile
alcohol wipe and sterile gauze. A standard rubber tourniquet was placed on the upper arm
and was tightened enough to slightly indent the arm, but not cause discomfort to the
participant. After palpating the vein, a twenty-two gauge sterile needle attached to a
vacutainer holder was inserted into the vein using standard procedure. Two serum
separator tubes were subsequently inserted into the vacutainer holder. After collecting
both samples, the needle and holder were removed. Needles were disposed of as
hazardous waste in a plastic sharps container. The site of needle entry was promptly
cleaned and pressure was applied using gauze to ensure proper clotting. All blood
collection tubes were labeled and placed in their respective racks. Properly trained and
clothed technicians, including research assistants, centrifuged the serum and plasma
samples, transferred the samples into storage containers, and stored them at -80oC for
later analysis. The USM Health Services Clinic ran a standard chemistry panel.
To determine the side effects of Xanthigen supplementation, participants were
given surveys to complete during each testing session. Questionnaires were confidentially
administered. Participants were asked to report whether their placebo or Xanthigen
15

supplement was tolerated, whether supplementation protocol was followed, and whether
any medical problems or symptoms were encountered throughout the study.
Finally, the data were analyzed by the lead investigator using SPSS for Windows
Version 17 software. Multivariate, repeated measures analyses of variance (MANOVAs)
were used to assess BMI, body composition, REE, lipid markers, and liver function
markers in a time versus supplement fashion. For further breakdown, separate, univariate
ANOVAs were performed to assess the main effects of the experiment. To be considered
significantly different, the probability of Type I error must be 0.05 or less. If a significant
difference was found between variables, Tukey’s honestly significant differences posthoc procedures was performed.
Chapter 4: Results
Demographic Data
Demographic data for Xanthigen and placebo groups are presented in Table 1
below. Upon baseline measures, there were no significant differences in age, body mass,
BMI, or body fat percentage. This indicates that the matching and randomization based
on these measures was successful.
Table 1: Demographic data collected at the beginning of the 16-week intervention†

16

Body Composition
Table 2 summarizes the changes seen in body composition, measured by DEXA,
after the 16-week protocol was completed. Multivariate ANOVA indicated no significant
main effects for time (p = 0.396), between group (p = 0.858), or group*time interaction
effect (p = 0.897). Although most participants successfully lost weight, body fat
percentage did not decrease in a similar fashion. Because body fat percentage did not
decrease as weight was lost, it was assumed that weight loss was due to a combination of
the loss of fat mass as well as lean mass. These findings are not consistent with the
findings of Abidov and colleagues.
Table 2: Body composition changes after the 16 week intervention†

Serum Lipids
Table 3 summarizes the observed changes in serum lipids over 16 weeks.
Multivariate ANOVA revealed a significant main effect for time (p = 0.043), but no
between group (p = 0.816) or group*time interaction effect (p = 0.201). After the
completion of a univariate analysis, it was determined that no significant changes were
found. This being said, there was a trend for decreased triglycerides (132 ±90 mg/dL to
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101 ± 58 in Xanthigen versus 138 ± 86 mg/dL to 133 ± 79 in placebo). HDL levels did
increase by 9.5% (from 42±9 to 46±8) in the Xanthigen group and by 6.8% in the placebo
group (44±12 mg/dL to 47±12 mg/dL). On the other hand, LDL levels decreased 8.1%
(111±29 mg/dL to 102±25 mg/dL) in the placebo group, but actually increased 8.3%
(109±37 mg/dL to 118±36 mg/dL) in the Xanthigen group. Total cholesterol also
decreased in the placebo group (183±30 mg/dL to 175±30 mg/dL) by 4.4%, but increased
in the Xanthigen group (177±34 mg/dL to 178±40 mg/dL) by 0.6%.
Table 3: Changes in serum lipids after the 16 week intervention†

Serum Markers of the Metabolic Syndrome and Hepatic Enzyme Levels
Table 4 summarizes the observed changes in markers of liver and kidney
function. Multivariate ANOVA revealed a significant main effect for time (p < 0.001),
but no between group (p = 0.327) or group*time interaction effect (p = 0.136). Univariate
analysis revealed a significant decrease in ALP (p = 0.001), ALT (p = 0.021) and a trend
for a decrease in AST (p = 0.062). Both groups showed a small decrease in ALP levels
over 16-weeks, although the Xanthigen group showed larger decreases (-7.8% versus
-5.5%, respectively). This indicated a significant change over time. AST levels decreased
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in both groups as well. The Xanthigen group decreased from 26 ± 16 U/L to 22 ± 13 U/L
(-15.4% change), while the placebo group decreased from 19 ± 5 U/L to 16 ± 7 U/L (15.8% change). While decreases were seen in both, these decreases were not considered
significant. Like AST, ALT levels significantly decreased over 16 weeks. Xanthigen
group decreased from 31 ± 27 U/L to 20 ± 8 U/L, indicating a -35.5% change. The
placebo group decreased from 21 ± 7 U/L to 18 ± 12 U/L, indicating a -14.3% change.
Multivariate ANOVA revealed no significant main effects for time (p = 0.066),
between group (p = 0.249), or group*time interaction effect (p = 0.966) for total
bilirubin, total protein, or albumin. Baseline levels of creatinine and blood urea nitrogen
(BUN) were significantly higher in the Xanthigen group than placebo at baseline, so
these variables were analyzed as delta changes from baseline. This analysis revealed a
significant main effect for time (p = 0.001), but no between group (p = 0.878) or
group*time interaction effect (p = 0.881). In the Xanthigen group, there was no change in
total bilirubin content (0.7 ± 0.4 to 0.7 ± 0.4 mg/dL), but the placebo group saw a -14.3%
change (0.7 ± 0.2 mg/dL to 0.6 ± 0.3 mg/dL). Both groups saw a decrease in creatinine –
-10.0% in the Xanthigen group (1.0 ± 0.1 mg/dL to 0.9 ± 0.2 mg/dL) and -11.1% in the
placebo group (0.9 ± 0.1 mg/dL to 0.8 ± 0.2 mg/dL). Blood urea nitrogen (BUN) did not
change in the Xanthigen group (14 ± 4 mg/dL to 14 ± 3 mg/dL), but increased in the
placebo group (11 ± 2 mg/dL to 12 ± 3 mg/dL). Total protein decreased in both groups as
well, -4.2% in Xanthigen (7.1 ± 0.4 g/dL to 6.8 ±0.4 g/dL) and -2.9% in the placebo
group (7.0 ± 0.3 g/dL to 6.8 ± 0.3 g/dL). While albumin did not change in the Xanthigen
group (4.5 ± 0.4 g/dL to 4.5 ± 0.4 g/dL), albumin levels increased in the placebo group by
2.3% (4.3 ± 0.4 g/dL to 4.4 ± 0.3 g/dL).
19

Table 4: Changes in serum markers of liver and kidney function after 16 weeks

Chapter 5: Discussion
When comparing the current study’s results to results from the Abidov study
(2010), there are some obvious differences. The Abidov study saw significant changes in
many areas that the current study did not. These differences are the likely result of the
small sample size of the current study and the large standard deviations presented with
these variables. Other variations in study design that could have attributed to these
different results involve the inclusion of obese men in the participant pool and not using a
standardized 1800 kcal diet, but instead individualizing participants’ caloric intake based
on their specific REE.
One of the most obvious differences between the current study and the Abidov
study (2010) is the change in body mass. Specifically, the Abidov study participants saw
a significant reduction in body mass after completing their 16-week intervention. In the
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current study, as a whole, participants significantly reduced their body mass, but this
reduction was not significantly greater in the Xanthigen group as it was with the Abidov
study. It is probable that this inconsistency is due to the small sample size of the current
study and the different diet criteria. Abidov strictly controlled the caloric intake of the
participants to 1800 kcals; since the current study included both male and female
participants, their diet was individualized based on their specific REE. Moreover, these
participants were only provided with dietary guidelines and biweekly monitoring, while
the previous study provided them with every meal.
Similar to body composition, there were inconsistencies between the Abidov
study (2010) and current study when examining changes in liver enzymes. Abidov and
colleagues saw significant reductions in ALT and AST with Xanthigen, but did not
investigate ALP. The current study showed significant declines in ALT and ALP overall,
but not as a result of Xanthigen. The current study also did not demonstrate a significant
change regarding AST either. Again, these differences are apparently due to the small
sample size of the current study and the large standard deviations.
The Abidov et al. (2010) study did not report cholesterol levels, but other lipids
were reported. Much like the Abidov study, triglyceride levels in the current study
decreased. This being said, the triglyceride levels in the current study dropped much
more than levels in the Abidov study. It is common to see HDL levels increase, while
LDL levels and triglycerides decrease with weight loss. It is probable that weight loss
produced the lipid improvements, rather than Xanthigen supplementation.
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While the Abidov study did not take into account kidney function markers, the
current study did. Although there were no significant changes between groups, there were
significant changes from baseline levels. The most important information gathered from
these measures was that these markers remained within safe and normal limits and were
unaffected by the Xanthigen supplementation.
Conclusion
Overall, Xanthigen supplementation did not produce the desired effects. Although
the Xanthigen group did see weight loss and slight improvements in serum markers, the
placebo group saw many of the same results, indicating that it was not necessarily the
Xanthigen supplementation that created the results seen. While this study did cover more
bases than previous studies regarding this supplement, there are some improvements that
could have been made. One key aspect for improvement would be to more carefully
monitor the diets of participants. Another way to improve the study would be to expand
the sample size of the study. Future studies on Xanthigen supplementation may consider
these options to have a more comprehensive study.
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